ASCO 2018 – Saturday, June 2

Saturday, June 2

8-11:30 a.m.
Hall A
POSTER SESSIONS:
Predicting neoadjuvant chemotherapy response from
pretreatment breast MRI using machine learning and
HER2 status
Poster #74; Abstract 582
Jame Abraham, MD – Author

NSABP FB-10: Phase 1b dose-escalation trial
evaluating trastuzumab emtansine (T-DM1) with
neratinib (N) in women with metastatic HER2+
breast cancer (MBC)
Poster #108; Abstract 1027
Jame Abraham, MD – First author

Prospective phase 2 multicenter study of
individualized axitinib (Axi) titration for metastatic
renal cell carcinoma (mRCC) after treatment with
PD-1/PD-L1 inhibitors
Poster #343; Abstract 4517
Moshe Ornstein, MD, MA – First author

Association of circulating tumor (CT)-DNA genomic
alterations (GA) with outcomes in metastatic
urothelial carcinoma (mUC)
Poster #366; Abstract 4540
Prateek Mendiratta, MD – Author

Correlation between gene expression and prognostic
biomarkers in small cell bladder cancer (SCBC)
Poster #372; Abstract 4546
Vadim Koshkin, MD – First author

8:36-8:48 a.m.
Hall D1
CLINICAL SCIENCE SYMPOSIUM:
Tumor Genomics: Finding the Target. Hitting the
Target. A phase 1 study of LOXO-292, a potent and highly
selective RET inhibitor, in patients with RET-altered cancers.
Abstract 102
Vamsidhar Velcheti, MD – Author

1:15-4:45 p.m.
Hall A
POSTER SESSIONS:
The prognostic impact of level 1 lymph node
involvement in oropharyngeal squamous cell carcinoma
Poster #60; Abstract 6072
Roy Xiao, BA – First author

Multiplex germline testing in selected melanomas
presenting to oncology clinic
Poster #159; Abstract 1588
Pauline Funchain, MD – First author

Effect of therapeutic pressure on stability of EGFR
amplification in glioblastoma
Poster #191; Abstract 2033
Manmeet Ahluwalia, MD – First author

Phase 2 trial of SurVaxM combined with standard
therapy in patients with newly diagnosed glioblastoma
Poster #199; Abstract 2041
Manmeet Ahluwalia, MD – First author

Phase 2 trial of SL-701 in relapsed/refractory
glioblastoma: immune response and longer-term survival
Poster #216; Abstract 2058
David Peereboom, MD – First author

Impact of apolipoprotein E (APOE) genotype on
neurocognitive function (NCF) in patients with brain
metastasis (BM): an analysis of NRG Oncology’s
RTOG 0614
Poster #223; Abstract 2065
John Suh, MD – Author

Implementation of individualized care plans in
high-risk oncology patients: a team-based model to
decrease unnecessary utilization
Poster #373; Abstract 6547
Girish Kunapareddy, MD – First author

1:51-2:03 p.m.
Hall D2
POSTER DISCUSSION SESSION:
Enrichment and Optimization of Anti-VEGF
Targeted Strategies in Metastatic Renal Cell Carcinoma
(Abstracts 4515, 4516, 4517)
Abstract 4517 – Prospective phase 2 multi-center
study of individualized axitinib (Axi) titration for
metastatic renal cell carcinoma (mRCC) after
treatment with PD-1/PD-L1 inhibitors
Moshe Ornstein, MD, MA – First author

5:24-5:36 p.m.
Hall B1
ORAL ABSTRACT SESSION:
ALT-803, an IL-15 superagonist, in combination
with nivolumab in metastatic non-small cell
lung cancer: ongoing experience and biomarker
development from a non-randomized, open-label, phase 1b/2 trial
Abstract 3008
Vamsidhar Velcheti, MD – Author